BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows ...

BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

BTIG analyst Clark Lampen raised the firm’s price target on DraftKings (DKNG) to $59 from $55 and keeps a Buy rating on the shares as part of a ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

Blank check company Rithm Acquisition, which is affiliated with Rithm Capital, filed for a $200 million initial public offering on Monday. The company said Michael Nierenberg, its chairman and chief ...

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...

BTIG Chief Market Technician Jonathan Krinsky thinks the market can “continue to make upside progress” into year-end and sees a new all-time high for the S&P 500 (SPX) above 6,100. However ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE <a target=_blank href= ...